|Publication number||US8182526 B2|
|Application number||US 12/756,361|
|Publication date||22 May 2012|
|Filing date||8 Apr 2010|
|Publication number||12756361, 756361, US 8182526 B2, US 8182526B2, US-B2-8182526, US8182526 B2, US8182526B2|
|Inventors||Azam Anwar, Georges A. Feghali, Kenneth B. Johnson|
|Original Assignee||Graft Technologies, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Non-Patent Citations (61), Classifications (2), Legal Events (1)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This Application is a continuation (and claims the benefit of priority under 35 U.S.C. §120) of U.S. application Ser. No. 11/483,121, filed Jul. 7, 2006, now U.S. Pat. No. 7,722,665 entitled “SYSTEM AND METHOD FOR PROVIDING A GRAFT IN A VASCULAR ENVIRONMENT,” Inventor(s) Azam Anwar, et al. The disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application.
This invention relates in general to vascular procedures and, more particularly, to a process, a system, and a method for providing a graft in a vascular environment.
The treatment of vascular diseases has grown exponentially in terms of sophistication and diversity. Procedures involving items such as stents or balloons are virtually routine in many health-care practices. However, despite vast advancements in many vascular procedures and medical devices, one particularly troublesome issue has remained in the field of kidney dialysis.
The number of patients requiring hemodialysis treatment grows at an alarming rate. Because patients generally require treatment until death or until kidney transplantation, the projection for the number of future hemodialysis procedures increases with each new group of patients.
Augmenting this problem is the prevalence of diabetes, which contributes directly to the number of patients requiring some form of kidney dialysis treatment. Currently, statistical data indicates that approximately twenty (20) million Americans have chronic kidney disease (CKD), while another twenty (20) million are at risk. Projections for the current population of patients with end-stage renal disease (ESRD) (which represents CKD patients requiring dialysis) are disturbing: reaching nearly 325,000 in 2002 with more than 100,000 patients beginning dialysis in 2003. Conservative estimates indicate that the prevalent rate of patients with ESRD is growing at approximately 3% per year and this rate is significantly higher in older populations (e.g. the 45-64 year range).
Concisely stated, current dialysis grafts are simply not ideal for a multitude of reasons. Many of the current shortcomings are described below in greater detail. These grafts can cause setbacks to the patient due to poor instrument design, adverse reactions from the patient's body, and higher costs for all individuals involved.
Accordingly, the ability to properly address vascular issues involving conduits within a suffering patient presents a significant challenge for device manufacturers, physicians, and surgeons alike.
From the foregoing, it may be appreciated by those skilled in the art that a need has arisen for an improved process for achieving superior flow, minimal stenosis, and optimal patency in a given vascular environment. In accordance with an embodiment of the present invention, a device, a system, and a method for facilitating optimal connections are provided that substantially eliminate or greatly reduce disadvantages and problems associated with conventional vascular devices, approaches, and strategies.
According to an embodiment of the present invention, an apparatus is provided that includes a graft for coupling two vascular conduits within a patient. The graft includes: 1) an anchor system that forms an arc at one end of the conduits; and 2) a body element coupled to the anchor system. The anchor system comprises a stent, which may be biodegradable, bioabsorbable, or biostable. In particular embodiments, portions of the graft are either self-expandable or balloon-expandable. In still other embodiments, the anchor system includes NITINOL and the anchor system is substantially self-sealing at one end of the conduits. The body element comprises polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (EPTFE), polyurethane derivatives, or any other suitable materials. In yet other embodiments, the body element includes either a gelatinous or an elastomeric coating disposed on its surface.
In still yet other embodiments, the body element includes two materials, whereby one of the materials biodegrades at a rate that is different from the other material. Additionally, both the body and the anchor may include a coating or a wrap to be used for drug loading and drug alluding.
In more specific embodiments, the graft may be accompanied by a delivery system that is used to direct the graft to a target location, the delivery system including a perforated sheath, a plunger, and a base that is coupled to the plunger, whereby actuation of the plunger can direct the graft to its target location. There are a myriad of possible design choices for the present invention, many of which are detailed below. The audience should be aware that the present invention is replete with potential design elections/alternatives or deviations from the specifications or examples provided herein in this document. Accordingly, the present invention and its appended claims should be construed to encompass all such modifications.
Certain embodiments of the present invention may provide a number of technical advantages. For example, according to one embodiment of the present invention, an architecture and a process are provided that offer a flexible AV graft system for a surgeon to utilize. The graft includes a hemodynamic profile, which reduces scarring or occlusion-type complications that would otherwise arise. In addition, the graft of the present invention offers a unique anchoring system that is stable and that is not prone to subsequent intimal hyperplasia. Many existing graft systems produce unwelcome radial forces, which present a significant danger to the patient. The present invention overcomes these deficiencies (as well as others) because the anchor of the graft can be secured within the vessel (vein or artery): yielding minimal radial forces. Radial forces must be accounted for because they can serve to injure vessels. In an ideal scenario, the graft is self-sealing; although various types of sutures can be used if this is not the case. In one example embodiment, an abrasive material can be used to create enough frictional force that the anchor is stabilized.
Moreover, the graft structure of the present invention is advantageous because it can be leveraged to deliver drugs locally: either through a stent, an anchoring system, the body of the graft, a coating, a wrap, or any other suitable element. Due to many of the aforementioned beneficial characteristics, the architecture of the present invention can provide a new graft solution with significantly higher long-term patency rates.
Certain embodiments of the present invention may enjoy some, all, or none of these advantages. Other technical advantages may be readily apparent to one skilled in the art from the following figures, description, and claims.
To provide a more complete understanding of the present invention and features and advantages thereof, reference is made to the following description, taken in conjunction with the accompanying figures, wherein like reference numerals represent like parts, in which:
For purposes of teaching and discussion, it is useful to provide some overview as to the way in which the following invention operates. The following foundational information may be viewed as a basis from which the present invention may be properly explained. Such information is offered earnestly for purposes of explanation only and, accordingly, should not be construed in any way to limit the broad scope of the present invention, its potential applications, and the appended claims.
For patients with end stage renal disease (ESRD), dialysis helps to remove waste, to balance certain chemicals in the blood, to remove excess fluid, and to control blood pressure. The survival of patients with ESRD is dependent on dialysis. There are two modalities of dialysis: hemodialysis and peritoneal dialysis, the former being the most common modality. In order to perform a hemodialysis procedure, a large vascular access is required. There are several methods of access available, several of which are outlined below.
Hemodialysis catheters are used in virtually all new patients, while they await the maturation of their permanent treatment method using an arteriovenous (AV) fistula or AV graft. A fistula is a tube-like passage that extends from a normal cavity or tube to a free surface or to another cavity. Fistulas are generally desirable as a long-term treatment method. However, there are drawbacks with fistulas because: 1) there is a limited number of vessels in many patients; 2) there is a high likelihood of failure in diabetics; 3) there are few favorable veins in diabetics (i.e. veins having sufficient width and elasticity); and 4) the problem of intimal hyperplasia at the venous anastomosis is still present.
Current AV grafts are used primarily when AV fistulas are not recommended due to age considerations or diabetic conditions. However, the development of a new type of AV graft with higher patency rates could make grafts the preferred method of access for hemodialysis. Another advantage of grafts is that grafts can be used almost immediately (such that puncturing of the graft is readily permitted), whereas fistulas need considerably more time.
Because most of the growth in hemodialysis patients is due to diabetes or due to patient age (ranging from 45 to 64 years old), the current AV fistula method is often not a viable option. Therefore, a growing number of patients require AV grafts. However, current graft solutions are problematic, as they have unacceptably low long-term patency rates.
The present invention overcomes these problems (and others) in providing an ideal graft that addresses the issues presented above. The proposed solution of the present invention introduces a new type of AV graft. The main benefits of the new graft are a hemodynamic profile, a unique anchoring system, an ability to deliver drugs, and an improved construction, which can accommodate the use of a biodegradable material. The architecture of the present invention also offers a new AV graft solution with significantly higher long-term patency rates and which is much safer for the patient.
Note that the most common cause of graft failure is stenosis of the outflow vein, resulting in graft thrombosis. Modalities to treat failed grafts include: 1) surgery; 2) angioplasty with balloons and/or stents; and 3) declotting using devices or drugs. The surgical revision using a jump graft may extend the access further up the arm to a more central location. However, after angioplasty, the access is immediately available for use and the available veins are saved for future use. Also, angioplasty is an easy and safe procedure, representing a superior solution, which is in contrast to repeated surgical revisions. A recent study has shown a 77% reduction in the intimal hyperplasia at the venous anastomosis using sirolimus-eluting stents, as compared to bare metal stents. The graft patency after an initial intervention is approximately 40%. As expected, longer stenoses and those lesions that have been dilated several times have less favorable patency rates.
In regards to the treatment of a clotted graft, the pulse-spray pharmacomechanical thrombolysis (PSPMT) helps to salvage around 75-94% of grafts. Statistical evidence suggests that the primary patencies range from 24% to 34% at 6-months and the secondary patencies may reach 80%. Thrombectomy devices have increased the efficiency and speed of thrombus removal and, in certain cases, obviate the use of thrombolytics. After a thrombectomy, the venous outflow stenosis should be treated. Thrombectomy of an infected graft is an absolute contra-indication since revascularization may lead to fatal sepsis. However, signs of infections can be very subtle and an infection can be missed. Other complications of thrombectomy include: anemia, bleeding, acute cardiac events, and venous and arterial embolism.
The proposed “Ideal Graft” of the present invention is a device that offers an optimal flow profile (producing minimal turbulence), that acts as a backbone for endothelial progenitor cells seeding (EPCs seeding), and that anchors to the vein through a system that can deliver anti-proliferate, anti-thrombotic, anti-platelet, and anti-inflammatory agents to the surrounding tissues. The graft's body and/or anchor can be biodegradable and the system, in certain embodiments, is sutureless, as outlined in greater detail below. The inside of the graft's body and/or anchor can be coated with anti-coagulants, anti-platelets, or thrombolytics. The present invention has advantages over existing systems because of its placement into a vessel, the two-component system (anchor and body), and all the potential design configurations that could be accommodated by such a device. In addition, the present invention can readily be used in artery-vein connections, vein-vein connections, and artery-artery connections (e.g. potentially involving the lower extremities). Many of the potential design choices are further detailed below with reference to the FIGURES.
Turning back to
Because repeat puncturing presents a significant bleeding issue for the patient [i.e. there is a sealing problem], the ePTFE can be coated with an elastomeric, gelatinous, or membrane that better accommodates improved sealing and a subsequent repuncture. ePTFE could be punctured immediately after being placed. In addition, ePTFE is beneficial because it is porous (which further allows tissue to grow directly on the device) and because it can be sewn into the vein. Tissue growth would essentially close the pores of the ePTFE.
Note that two preeminent considerations in constructing the graft are flow dynamics and the optimal delivery of drugs. For the patient, scarring would commence immediately after the procedure was performed and, hence, the drug aspect of the device is crucial. Venous stenosis will present a significant issue for both the patient and the physician; however the acuteness of this issue will be lessened considerably by optimal drug applications. The graft itself will stabilize with in-growth, shortly after placement.
The use of sutures will assist in this stabilization. Such sutures may be of a conventional type, purse string, interrupted sutures, or they may use a screw-type configuration in which pressure applied to the head of the suture translates into a rotational force that secures/tightens an intermediate object in place. In an ideal scenario, the graft secures itself (i.e. self-sealing) after the dilator and the splittable sheath are removed from the target site, whereby little of the graft anchor (e.g. NITINOL or any other suitable composite) is left exposed. However, in cases where stabilization is tenuous, then suturing (either at points 18, or 20 on the venous side where the anchor system is present) would be performed.
In order to avoid kinking, spatulation techniques may be employed. In addition, an abrasive material (either a coating or the underlying structure itself) may be used to seat the device. This material could provide a frictional resistive force that would inhibit movement on the anchor side where stabilization is more tenuous.
As evidenced by
In one embodiment, the graft is constructed of a self-expandable NITINOL anchor, which can readily be compressed before the device is placed. In other embodiments, the NITINOL could be replaced by any other suitably metal or alloy. In certain instances, NITINOL may be prone to fracturing and thus, other metals may be used without departing from the spirit and scope of the present invention. Virtually any material that gives structural integrity to the graft can be used. The expansion property of the anchor would allow the venous side to expand over time. The radial strength can be selected based on matching potential compliance with the vein or specific vein characterizes. For placement of the graft, the NITINOL anchor portion would be suitably compressed and then insertion of the device would occur on the venous side.
In particular embodiments, the proposed graft anchor is constructed of a biodegradable material that can dissolve (to varying degrees) in the body of the patient. Note that the cover or shell of the graft could be biodegradable, whereby an underlying latticework structure is used that is not biodegradable. This represents the use of at least two materials. In such a case, the underlying structure could be spiral or cylindrical, such as that depicted by
In certain instances, the entire graft could be biodegradable. Hence, the graft could be partially biodegradable or fully biodegradable. It should also be recognized that two different biodegradable materials could be used in combination such that one material could dissolve more slowly than the other material. The slower dissolving material could function as a backbone or a skeleton for the graft: providing support for the device as it acclimates to its new environment. Any such permutations are clearly with the broad scope of the present invention.
In one embodiment, anchor 12 comprises a biodegradable material such that, over time, anchor 12 would dissolve at a selected pace. Any drug agent could be used to facilitate a dissolution objective of anchor 12. A coating or a wrap (e.g. a polymer, a fibrous material, etc.) could be used to assist in the drug deliver and/or assist in connecting or supporting anchor 12. Thus, in one example scenario, a simple polymer could be used on the surface of anchor 12 to inhibit fibrointimal hyperplasia (i.e. excessive growth of tissue).
Body 14 could comprise ePTFE, a polyurethane derivative, an elastomeric composite, or a gelatinous material. In one example, body 14 is not necessarily biodegradable such that it maintains its structural integrity. Other embodiments however allow body 14 to biodegrade (to varying degrees).
In terms of placement of the graft and its potential design [in the artery and vein combination embodiment], body 14 could be in the range of 3-9 millimeters in one example. Anchor 12 could extend 1-60 centimeters into a vessel (artery or vein) once it has been positioned. In general, there is little downside risk to having the anchor extend further into the vessel, as opposed to less. The longer the anchor, the more stable the device. Some obvious drug applications for the anchor would include heparin or any other suitable anticoagulant or anti-platelet.
The arc created by anchor 12 could be of any suitable degree measurement (e.g. 45 degrees), but in any event, should universally be gradual or smooth. The smoothness of the arc will facilitate a preferred hemodynamic profile. If the angle is too acute, the system will clot off, which is undesirable. A 90-degree angle, for example, would not be ideal and may cause the graft to kink or cause blood turbulence. The actual thickness or diameter of anchor 12 and/or body 14 could be in the range of 3-6 millimeters, while the small lip formed by the vein on one end of body 14 could be approximately 1.5 millimeters. Note that all of these specifications are only being provided by way of example. These measurements may be departed from considerably while still achieving the teachings of the present invention.
One important issue in procedures involving the graft of the present invention involves exposing the vein to various drugs, which can assist in the healing process and/or inhibit complications that normally occur in dialysis scenarios. In general, the venous side is more problematic and, hence, higher dosages of drugs should be delivered there. Such drug applications could have dosages that release over long periods of time; ideally, the longer the drug delivery, the better. It should also be noted that the selection of veins is critical. Veins less than 2 millimeters would probably not be feasible for such a graft procedure. Vein selection could be aided by sonography or other adequate technologies. It should also be noted that a Seldinger approach may be preferred to a simple veinotomy.
One function of anchor 12 is to ensure that the graft is attached to the vein. In still another example deployment, anchor 12 is positioned about 2-3 centimeters into the vein. Anchor 12 is designed such that, in its compressed or delivered state, it is relatively small in comparison to the point of entry. The material of anchor 12 has a memory such that when a surgeon releases it at the appropriate location, it will occupy a much larger area. Hence, once anchor 12 has been inserted into the vein, it can be deployed or expanded such that is provides an appropriate resistive force, pressure, or friction, which enables anchor 12 to be somewhat resistant to movement. This feature of anchor 12 minimizes radial forces and hyperplasia issues at this site.
Note that the vein in this example does not have to be necessarily ligated. The positioning of the graft obviates the need to perform additional ligating procedures that address small branches associated with this vein. The placement of the graft has the effect of excluding these branches, rather than having to address each one individually.
Note that vascular access related problems currently account for more than 25% of all hospitalizations among ESRD patients. Infections, peri-graft seroma, and pseudoaneurysm constitute less than 10-15% of graft failure. Instead, the majority is due to graft thrombosis, which is the result of disproportionate intimal hyperplasia at the venous outflow tract. The intimal hyperplasia responses occur (predominantly) in the proximal 2-3 cm of the vein just distal to the graft-vein anastomosis. The pathophysiological mechanisms behind the reactive intimal hyperplasia are believed to be due to increases of flow and to vascular injury. Anchor 12 achieves significant advantages over existing graft systems in that anchor 12 is secured within the vein and yields minimal radial forces. Radial forces must be accounted for because they can serve to injure vessels or the vein itself.
On the artery side of the graft (where the surgeon is facilitating a connection between a vein and an artery), body 14 is attached via anastomosis by suturing. A number of drugs may be disposed on, or within, body 14. For example, anti-coagulants, anti-thrombic, or growth factors may be used in such a scenario. The growth factors may be used in order to recruit endothelial progenitor cells that expedite recovery for a patient. The growth factors may also be used in order to encourage the formation of new structures (e.g. vessels) at this site.
Hence, the inside (or exterior) of the graft can be coated with, for example, a CD34 antigen. Additionally, any number of drugs can be used for coatings and wraps (e.g. sirolimus, paclitaxel, everolimus, ABT-578, mycophenolic acid, tacrolimus, estradiol, oxygen free radical scavenger, biolimus A9, anti-CD34 antibodies, PDGF receptor blockers, MMP-1 receptor blockers, VEGF, G-CSF, HMG-CoA reductase inhibitors, stimulators of iNOS and eNOS, ACE inhibitors, ARBs, doxycycline, thalidomide, etc.).
In operation of an example embodiment, consider the case of a patient who is experiencing kidney failure. The surgeon in this situation has elected to offer this patient a graft, as outlined herein. There are two incisions that are made by the surgeon: one at the artery and one at the vein. These incisions effectively localize the vein and the artery. A wire can then be inserted into the vein. The present invention can be positioned over the wire, whereby the graft is deployed. (Note that the present invention may also be deployed in a percutaneous fashion, which is further detailed below.) Anchor 12 is then suitably positioned within the vein. An effective positioning of anchor 12 operates to prevent back-slipping or bleeding on the venous side. The wire is subsequently removed from the surgical site. Body 14 can then be sutured to the artery.
In the percutaneous solution, entry can be from the venous or the arterial side. For purposes of discussion, the venous side solution is explained here. First, the target vein is accessed via a sheath in a conventional manner. Subsequently, a needle (which is specially designed to include a curve) that includes a hole is inserted into the sheath. Note that, for purposes of fluoroscopy, dye may also be injected into the patient, whereby a simple turnikit is used to stop the flow of blood.
With the target under fluoroscopy, the objective is to puncture the wall of the artery where the dye has accumulated. Then a wire can be inserted into the artery and the sheath can be advanced over the wire and directed to the artery. Thus, the sheath is now positioned between the vein and the artery. Now the environment is ready for the graft. As is described above, anchor 12 is positioned on the venous side. In addition, body 14 is coupled to the arterial side in any suitable manner (e.g. using a resistive force mechanism, using footers or legs that hold body 14 in place, using a funnel shaped design, etc.).
Turning now to the next set of FIGURES,
In addition, the graft material for this example design is ePTFE throughout the graft's length, where a NITINOL scaffold (about 3.5 centimeters) is provided to cover the distal end. A drug-eluting coating is provided to inhibit intimal hyperplasia. For example, the use of drugs such as rapamycin (or other similar drugs) may be used for their antiproliferative properties. Additionally, in the implementation of
In one sense, this particular embodiment is different from the aforementioned devices (discussed above) in that it is a full anchor design: capitalizing on the anchor technology discussed heretofore. In this complete anchor design, a suitable material (such as those coatings, polymers, and layers highlighted above, including the materials identified in the US patent numbers referenced previously) is disposed on the surface of the stent. In other instances, the material is placed within the stent, or any suitable combination being provided exterior to or within the device.
This device can be in the range of 8-200 millimeters, although such a parameter could be changed based on particular needs. This stent could be used in a multitude of environments, including: bypass grafts, dialysis grafts, carotid applications, vein grafts, peripheral arteries, as an esophageal and bronchial scaffold to deliver structure and drugs to a targeted area, or in any other vasculature or endovascular setting.
As highlighted in the corresponding FIGURES, the device in this situation could easily be placed percutaneously.
It is important to note that the stages and steps in the preceding FIGURES illustrate only some of the possible scenarios that may be executed by, or within, the architecture of the present invention. Some of these stages and/or steps may be deleted or removed where appropriate, or these stages and/or steps may be modified or changed considerably without departing from the scope of the present invention. In addition, a number of these operations have been described as being executed concurrently with, or in parallel to, one or more additional operations. However, the timing of these operations may be altered considerably. The preceding example flows have been offered for purposes of teaching and discussion. Substantial flexibility is provided by the proffered architecture in that any suitable arrangements, chronologies, configurations, and timing mechanisms may be provided without departing from the broad scope of the present invention.
Although the present invention has been described in detail with reference to particular embodiments in
Additionally, although the preceding FIGURES have described a body-anchor combination, another possibility of the present invention could be two anchors. In such a case, both anchors would seat directly in the vessel. It should also be noted yet again that the present invention is not limited to vein-artery connections, as vein-vein and artery-artery scenarios can certainly be accommodated by the present invention.
It is also imperative to note that although the present invention is illustrated as implicating a number of conventional procedures, the present invention could be completely percutaneous, as highlighted above. In essence, the present invention may be applicable to a multitude of environments in which a viable conduit is needed.
Numerous other changes, substitutions, variations, alterations, and modifications may be ascertained to one skilled in the art and it is intended that the present invention encompass all such changes, substitutions, variations, alterations, and modifications as falling within the spirit and scope of the appended claims. In order to assist the United States Patent and Trademark Office (USPTO) and additionally any readers of any patent issued on this application in interpreting the claims appended hereto, Applicant wishes to note that the Applicant: (a) does not intend any of the appended claims to invoke paragraph six (6) of 35 U.S.C. section 112 as it exists on the date of filing hereof unless the words “means for” are specifically used in the particular claims; and (b) does not intend by any statement in the specification to limit his invention in any way that is not otherwise reflected in the appended claims.
|1||A. Colombo, et al., "Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions," Circulation, vol. 108, cover page and pp. 788-794, Jul. 10, 2006.|
|2||A. Jawien, et al., "Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty," www.pubmed.gov (abstract only), J Clin Invest., Jul. 25, 2006, 89(2):507-11.|
|3||A.C. Newby, et al., "Molecular mechanisms in intimal hyperplasia," www.pubmed.gov (abstract only), J Pathol Jul. 25, 2006, 190(3):300-9.|
|4||A.Leuprecht, et al., "Numerical study of hemodynamics and wall mechanics in distal end-to-side anastomoses of bypass grafts," Journal of Biomechanics, vol. 35, pp. 225-236, © 2002.|
|5||Angiotech Pharmaceuticals, Inc., "Angiotech completes acquisition of Lifespan(R) vascular graft product line from Edwards Lifesciences," http://biz.yahoo.com/prnews/, Printed Dec. 1, 2005, 2 pages.|
|6||Boston Scientific, "PTCA with Stent," http://www.bostonscientific.com, Printed Jun. 28, 2006, 9 pages.|
|7||D. Kirsch, M.D., et al., "In Vitro Evaluation of Side-Branch Creation in Metal Stents by Balloon Dilation," The Journal of Applied Research, vol. 3, No. 4, Fall, 2003, pp. 380-387.|
|8||D. Mehta, et al., "External stenting reduces long-term medial and neointimal thickening and platelet derived growth factor expression in a pig model of arteriovenous bypass grafting," www.pubmed.gov (abstract only), Nat Med., 4(2):235-9, Feb. 1998.|
|9||D. Vorwerk, M.D., et al., "Venous Stenosis and Occlusion in Hemodialysis Shunts: Follow-up Results of Stent Placement in 65 patients," Radiology, vol. 195, No. 1, pp. 140-146, 1995.|
|10||D.H. Walter, et al., "Statin Therapy Accelerates Reendothelialization: A Novel Effect involving Mobilization and incorporation of Bone Marrow-Derived Endothelial Progenitor Cells," Circulation, vol. 105, cover page and pp. 3017-3024, Jul. 10, 2006.|
|11||G. Kalmar, M.D., et al., "Radial Force and all Apposition of Balloon-expandable Vascular Stents in Eccentric Stenoses: An In Vitro Evaluation in a Curved Vessel Model," http://www.jvir.org/cgi/content/full/13/5/499, Journal of Vascular and Interventional Radiology, vol. 13, pp. 499-508, © 2000 The Society of Cardiovascular & Interventional Radiology; http://www.jvir.org/cgi/content/full/13-5-499; Printed Jun. 28, 2006.|
|12||G. Pertosa, et al., "Clinical relevance of cytokine production in hemodialysis," www.pubmed.gov (abstract only), Kidney Int Suppl., Jul. 25, 2006, 76: S104-11.|
|13||G.A. Beathard, "Percutaneous transvenous angioplasty in the treatment of vascular access stenosis," www.pubmed.gov (abstract only), Kidney Int. 42(6):1390-7, Dec. 1992.|
|14||G.R. Grotendorst, et al., "Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells," www.pubmed.gov (abstract only), J Cell Physiol. Jul. 25, 2006, 113(2):261-6.|
|15||H. King, M.D., DSC, et al., "Global Burden of Diabetes, 1995-2025: Prevalence, numerical estimates, and projections," Diabetes Care, vol. 21, No. 9, Sep. 1998, pp. 1414-1431.|
|16||H. Rakugi, et al., "Vascular injury induces angiotensinogen gene expression in the media and neointima," Circulation, vol. 87, No. 1, Jul. 11, 2006, cover page and pp. 283-290.|
|17||H.I. Feldman, et al., "Hemodialysis Vascular Access Mobility," Journal of the American Society of Nephrology, vol. 7, No. 4, 1996, pp. 523-535.|
|18||Ho-Wook Jun, et al., "Nitric Oxide-Producting Polyurethanes," © 2005 American Chemical Society, Biomacromolecules, vol. 6, No. 2, Published on Web Jan. 19, 2005, pp. 838-844.|
|19||Hyun-Jai Cho, et al., "Mobilized Endothelial Progenitor Cells by Granulocyte-Macrophage Colony-Stimulating Factor Accelerate Reendothelialization and Reduce Vascular Inflammation After Intravascular Radiation," Circulation, 108:2918-25, Jul. 10, 2006.|
|20||J. Barton, et al., "PhotoPoint photodynamic therapy inhibits intimal hyperplasia in arteriovenous access grafts," www.pubmed.gov (abstract only), Cardiovasc Radiat Med., 3(3-4): 147-51, Jul.-Dec. 2002.|
|21||J. Llevadot, et al., "HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells," Journal of Clinical Investigation, vol. 108, No. 3, pp. 399-405, Aug. 2001.|
|22||J.E. O'Brien, Jr., et al., "Early Injury to the Media after Saphenous Vein Grafting," The Annals of Thoracic Surgery, vol. 65, Issue 5, http://www.scincedirect.com (abstract only), © 1998, pp. 1273-1278.|
|23||J.E. Rosenman, et al., "Kinetics of endothelial seeding," www.pubmed.gov (abstract only), J Vasc Surg. 2(6):778-84, Nov. 1985.|
|24||J.I. Rotmans, et al., "Hemodialysis access graft failure: Time to revisit an unmet clinical need?" Journal of Nephrology, vol. 18, No. 1, http://www.sin-italy.org/jnonline/Vol18n1/9.html, Printed Aug. 4, 2006, 14 pages.|
|25||J.I. Rotmans, et al., "Rapid, arteriovenous graft failure due to intimal hyperplasia: a porcine bilateral, carotid arteriovenous graft model,"www.pubmed.gov (abstract only), J Surg Res., Jul. 25, 2006, 113(1):161-71.|
|26||J.I. Rotmans, et al., "Sirolimus-Eluting Stents to Abolish Intimal Hyperplasia and Improve Flow in Porcine Arteriovenous Grafts: A 4-Week Follow-up Study," Circulation, vol. 111, cover page and pp. 1537-1542, Jul. 10, 2006.|
|27||J.I. Rotmans, M.D., et al., "Matrix metalloproteinase inhibition reduces intimal hyperplasia in a procine arteriovenous-graft model," http://www.sciencedirect.com (abstract only), J Vasc Surg., vol. 39, Issue 2, pp. 432-439, Feb. 2004.|
|28||J.J. Castellot, Jr., et al., "Cultured Endothelial Cells Produce a Heparinlike Inhibitor of Smooth Muscle Cell Growth," Journal of Cell Biology, vol. 90, Aug. 1981, pp. 372-379.|
|29||J.S. Kaufman, et al., "Randomized Controlled Trial of Clopidogrel plus Aspirin to Prevent Hemodialysis Access Graft Thrombosis," J Am Soc Nephrol. vol. 14, pp. 2313-2121, © 2003.|
|30||M. Deutsch, et al., "Clinical autologous in vitro endothelialization of infrainguinal ePTFE grafts in 100 patients: a 9-year experience," www.pubmed.gov (abstract only), Surgery, 126(5):847-55, Nov. 1999.|
|31||M. Rekhter, et al., "Cell proliferation in human arteriovenous fistulas used in hemodialysis," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 13, No. 4, Jul. 11, 2006, cover page and pates 609-17.|
|32||M.C. Morice, et al., "A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revasculatization," www.pubmed.gov (abstract only), N Eng J Med., 346(23):1773-80, Jun. 2002.|
|33||M.F. Weiss, et al., "Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access," www.pubmed.gov (abstract only), AmJ Kidney Dis., Jul. 25, 2006, 37(5):970-80.|
|34||M.J. Daemen, et al., "Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall," Circ. Res. vol. 68, No. 2, Jul. 11, 2006, cover page and pates 450-6.|
|35||M.J. Englesbe, et al., "Concomitant blockade of paletelet-derived growth factor receptors alpha and beta induces intimal atrophy in baboon PTFE grafts," www.pubmed.gov (abstract only), J Vasc Surg. 39(2):440-6, Feb. 2004.|
|36||M.P. Bendeck, et al., "Doxycycline Modulates Smooth Muscle Cell Growth, Migration, and Matrix Remodeling after Arterial Injury," American Journal of Pathology, vol. 160, No. 3, pp. 1089-1095, Nov. 14, 2001.|
|37||M.R. Kibbe, et al., "Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia," www.pubmed.gov (abstract only), J Vasc Surg., 34(1):156-65, Jul. 2001.|
|38||Non-Final Office Action in U.S. Appl. No. 11/483,121 mailed on Jul. 29, 2009.|
|39||Non-Final Office Action in U.S. Appl. No. 12/756,395 mailed on Aug. 23, 2011.|
|40||Notice of Allowance in U.S. Appl. No. 11/483,121 mailed on Jan. 14, 2010.|
|41||Notice of Allowance in U.S. Appl. No. 12/756,395 mailed on Jan. 5, 2012.|
|42||P. Roy-Chaudhury, et al., "Venous neointimal hyperplasia in polytertrafluoroethylene dialysis grafts," , www.pubmed.gov (abstract only), Kidney Int., 59(6):2325-34, Printed Aug. 4, 2006.|
|43||P.J. Gagne, et al., "The effect of venous anastomosis Tyrell vein collar on the primary patency of arteriovenous grafts in patients undergoing hemodialysis," www.pubmed.gov (abstract only), J Vasc Surg. 32(6):1149-54, Dec. 2000.|
|44||P.L. McNeil, et al., "Growth Factors are Released by Mechanically Wounded Endothelial Cells," Journal of Cell Biology, vol. 109, Aug. 1989, pp. 811-822.|
|45||R. Dammers, et al., "Evaluation of 4-mm to 7-mm versus 6-mm prosthetic brachial-antecubital forearm loop access for hemodialysis: results of a randomized multicenter clinical trial," www.pubmed.gov (abstract only), J Vasc Surg. 37(1):143-8, Jan. 2003.|
|46||R. Saran, et al., "Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS)," www.pubmed.gov (abstract only), Am J Kidney Dis. 40(6):1255-63, Dec. 2002.|
|47||R.Y. Kanterman, M.D., et al., "Dialysis Access Grafts: Anatomic Location of Venous Stenosis and Results of Angioplasty," Interventional Radiology, vol. 195, No. 1, 1995, pp. 135-139.|
|48||Response to Non-Final Office Action dated Aug. 23, 2011 in U.S. Appl. No. 12/756,395, filed Nov. 23, 2011.|
|49||Response to Non-Final Office Action dated Jul. 29, 2009 in U.S. Appl. No. 11/483,121, filed Oct. 22, 2009.|
|50||Response to Restriction Requirement dated Jun. 10, 2009 in U.S. Appl. No. 11/483,121, filed Jun. 15, 2009.|
|51||Restriction Requirement in U.S. Appl. No. 11/483,121 mailed on Jun. 10, 2009.|
|52||S. Sun, et al., "Inhibitory effect of brachytherapy on intimal hyperplasia in arteriovenous fistula," www.pubmed.gov (abstract only), J Surg Res. 115(2):200-8, Dec. 2003.|
|53||S.H. Swedberg, et al., "Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patents, Clinical, immunocytochemical, light and electroni microscopic assessment," Circulation, vol. 80, No. 6, Jul. 11, 2006, cover page and pp. 1726-1736.|
|54||U.S. Appl. No. 12/756,395, filed Apr. 8, 2010, entitled "System and Method for Providing a Graft in a Vascular Environment", Inventor(s): Azam Anwar, et al.|
|55||V. Bhattacharya, et al., "Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34* bone marrow cells," Hemostasis, Thrombosis, and Vascular Biology, vol. 93, No. 2, pp. 581-585, Jan. 15, 2000.|
|56||V. Hoang, "Stent Design and Engineer Coating Over Flow Removal Tool—Team #3 (Vimage)," Oct. 29, 2004, 9 pages.|
|57||V. Lindner, et al., "Role of basic fibroblast growth factor in vascular lesion formation," Circ. Res., vol. 68, No. 1, Jul. 11, 2006, cover page and pates 106-13.|
|58||V.M. Rodriguez, M.D., et al., "Effects of Brachytherapy on Intimal Hyperplasia in Arteriovenous Fistulas in a Porcine Model," J Vase Interv Radiol., vol. 13, No. 12, pp. 1239-1246, © 2002.|
|59||W. Schmidt, et al., "Comparison of mechanical properties of peripheral self-expanding Nitinol and balloon-expandable stainless-steel stents," Electronic Poster, Annual Meeting and Postgraduate Course, Cardiovascular and Interventional Radiological Society of Europe (CIRSE), Barcelona, Spain, Sep. 29, 2004; 7 pages.|
|60||W. Trubel, et al., "Compliance mismatch and formation of distal anastomotic intimal hyperplasia in externally stiffened and lumen-adapted venous grafts," www.pubmed.gov (abstract only), Eur. Vasc Endovasc Surg., Jul. 25, 2006, 10(4):415-23.|
|61||W.M. Abbott, et al., "Effect of compliance mismatch on vascular graft patency," www.pubmed.gov (abstract only), J Vasc Surg., Jul. 25, 2006, 5(2):376-82.|
|8 Apr 2010||AS||Assignment|
Owner name: GRAFT TECHNOLOGIES, INC.,TEXAS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANWAR, AZAM (NMI);FEGHALI, GEORGES A.;JOHNSON, KENNETH B.;SIGNED BETWEEN 20060702 AND 20060707;REEL/FRAME:24206/391
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANWAR, AZAM (NMI);FEGHALI, GEORGES A.;JOHNSON, KENNETH B.;SIGNING DATES FROM 20060702 TO 20060707;REEL/FRAME:024206/0391
Owner name: GRAFT TECHNOLOGIES, INC., TEXAS